Trends in Molecular Medicine
Ebola virus: unravelling pathogenesis to combat a deadly disease
Section snippets
Molecular biology of Ebola virus
Ebola viruses (EBOV) belong to the Filoviridae family (order Mononegavirales). The genus Ebolavirus (EBOV) is subdivided into four species: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Ivory Coast ebolavirus (ICEBOV) and Reston ebolavirus (REBOV) [1].
The 18.9-kb RNA genome of EBOV is non-infectious and encodes seven structural proteins and one non-structural protein in the following order within the genome: 3′ non-coding region (leader), nucleoprotein (NP), virion protein 35 (VP35),
Epidemiology
Since its identification in 1976, there have been 1849 reported cases of Ebola haemorrhagic fever (EHF) including 1288 deaths (Table 1); all the outbreaks occurred in the tropical African ecosystem and were located between latitudes 5° North and 5° South. The epidemiology of human Ebola virus infections in nature is unknown. However, the time between the occurrence of index cases and the recognition of subsequent large outbreaks, in addition to the possible occurrence of asymptomatic
Clinical presentation
EBOV infection in humans and NHPs results in a particularly virulent form of viral haemorrhagic fever. Following an incubation of 4–10 days [2], fever of >38.3°C abruptly develops. Additional early symptoms are non-specific and can include chills, muscle pain, nausea, vomiting, abdominal pain and/or diarrhoea 8, 9, 10. Swelling of the lymph nodes, kidneys or brain, as well as necrosis of the liver, lymph organs, kidneys, testis and ovaries can occur. All patients show some extent of impaired
Animal models
In recent years, there has been significant progress towards the understanding of the pathogenic mechanisms that underlie EHF. However, there are only limited data regarding the pathophysiology of EHF in humans owing to the occurrence of outbreaks in remote areas and the lack of facilities that enable safe and thorough investigations during an outbreak 16, 17. Therefore, the development of animal models for EHF has been invaluable in increasing the knowledge of EBOV pathogenesis. At present,
Treatment
At present, the treatment for EHF is mainly supportive and involves a combination of intravenous-fluid replacement, administration of analgesics and standard nursing measures [25].
Despite the lack of any specific antiviral drugs for the treatment of EHF, a few experimental approaches have shown promise in recent years. In particular, because overexpression of TF has such a profound effect in the development of DIC, the possibility of inhibiting this pathway has been considered as a therapeutic
Concluding remarks
EBOV is a highly pathogenic virus that has caused an increasing number of outbreaks in central Africa in the past decade. Because of its high fatality rate and potential use as a bioweapon, it is very important to understand its mechanisms of pathogenesis and, ultimately, to develop vaccines and therapeutics.
The current model for EBOV pathogenesis is that, after entering the host, EBOV targets macrophages and DCs, thereby inducing an inflammatory state with high levels of proinflammatory
Acknowledgements
The authors gratefully acknowledge H. Ebihara (Institute for Medical Science, University of Tokyo, Japan) and S. Becker (Philipps Universität Marburg, Germany) for their valuable discussion, and S. Bamberg and L. Kolesnikova (Philipps Universität Marburg, Germany) for providing source material for the figures. Work on filoviruses at the National Microbiology Laboratory is supported by the Public Health Agency of Canada, the Canadian Institutes of Health Research (MOP-43921) and the National
Glossary
- Adaptive immunity:
- components of the immune system that are acquired after birth. These are characterized by specific immune responses to an antigen, including antibody production by B cells, selection of active T cells, T-cell apoptosis and development of immunological memory.
- Animal model:
- refers to an animal species that is sufficiently similar to humans in its response to an injury or disease so that it can be used in medical research to obtain information that can be extrapolated for human
References (95)
Pathogenesis of viral hemorrhagic fever
Curr. Opin. Immunol.
(2005)Molecular characterization of guinea pig-adapted variants of Ebola virus
Virology
(2000)Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses
Lab. Invest.
(2000)- et al.
Pathogenesis of filoviral haemorrhagic fevers
Lancet Infect. Dis.
(2004) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection
Am. J. Pathol.
(2003)Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice
J. Comp. Pathol.
(2001)Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells
Am. J. Pathol.
(2003)Human asymptomatic Ebola infection and strong inflammatory response
Lancet
(2000)Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1α and TNF-α and inhibit poly-IC-induced IFN-α in vitro
Virology
(2001)Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells
Virology
(1998)
Ebola and Marburg virus-like particles activate human myeloid dendritic cells
Virology
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily
Immunol. Lett.
Innate immune responses to infection
J. Allergy Clin. Immunol.
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys
Lancet
Δ-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus
Virology
Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor
Virology
The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses
FEBS Lett.
Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus
Vaccine
Filoviridae
Ebola between outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981–1985
J. Infect. Dis.
Ebola virus: from discovery to vaccine
Nat. Rev. Immunol.
Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure
J. Infect. Dis.
Fruit bats as reservoirs of Ebola virus
Nature
Experimental inoculation of plants and animals with Ebola virus
Emerg. Infect. Dis.
Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients
J. Infect. Dis.
Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation
J. Infect. Dis.
First hand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire
Rev. Infect. Dis.
Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola)
J. Infect. Dis.
Exotic emerging viral diseases: progress and challenges
Nat. Med.
Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome
J. Virol.
Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels
J. Virol.
Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995
J. Infect. Dis.
Ebola and Marburg viruses: pathogenesis and development of countermeasures
Curr. Mol. Med.
Animal pathology of filoviral infections
Curr. Top. Microbiol. Immunol.
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever
J. Infect. Dis.
Pathogenesis of experimental Ebola virus infection in guinea pigs
J. Infect. Dis.
Of mice and not men: differences between mouse and human immunology
J. Immunol.
Therapy and prophylaxis of Ebola virus infections
Curr. Opin. Investig. Drugs
Evaluation in nonhuman primates of vaccines against Ebola virus
Emerg. Infect. Dis.
An analysis of features of pathogenesis in two animal models of Ebola virus infection
J. Infect. Dis.
Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity
Science
Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture
J. Virol.
The role of reverse genetics systems in studying viral hemorrhagic fevers
Thromb. Haemost.
Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages?
Clin. Infect. Dis.
Infection and activation of monocytes by Marburg and Ebola viruses
J. Virol.
Cited by (135)
Lateral flow assays for viruses diagnosis: Up-to-date technology and future prospects
2022, TrAC - Trends in Analytical ChemistrySynthetic nanobody-functionalized nanoparticles for accelerated development of rapid, accessible detection of viral antigens
2022, Biosensors and BioelectronicsNanoparticle-based immunoassays for early and rapid detection of HIV and other viral infections
2022, Nanotechnological Applications in VirologyEbola outbreak in West Africa, 2014 – 2016: Epidemic timeline, differential diagnoses, determining factors, and lessons for future response
2020, Journal of Infection and Public HealthPathogenic viruses: Molecular detection and characterization
2020, Infection, Genetics and EvolutionCitation Excerpt :Mature EBOV particles form long filamentous rods with a diameter of about 80 nm. The length of the virus varies greatly, with mean of about 1250 nm (Hoenen et al., 2006; Rivera and Messaoudi, 2016; Baseler et al., 2017). Molecular methods based on PCR amplification of Ebola genome fragments have been developed and implemented for detection of Ebola virus.